Micrima Signs Distribution Agreement with Hologic for its Novel Breast Imaging System MARIA®

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Micrima Ltd (the “Company”), the breast imaging company, is pleased to announce that it has signed a distribution agreement with Hologic Inc., a global leader in women’s health, for the Company’s new radio-wave breast imaging system, MARIA®. Under the terms of the agreement, Hologic will act as the sales and distribution partner for Micrima in Germany, Austria and Switzerland (DACH).

The first installations of MARIA®, which received CE mark approval in 2015, are expected to take place in Germany in the coming months.

Micrima has been working to develop a breast imaging system that can be used frequently from a young age to reduce the number of deaths from breast cancer. MARIA® uses harmless radio-waves, does not require breast compression and is cost effective to use. Trials to date have proven that, as an adjunct to X-ray mammography, it is effective at locating cancers, particularly in the dense tissue associated with younger women. The Company plans to introduce tissue differentiation within the MARIA® scan as it rolls out higher levels of functionality over time.

Roy Johnson, Micrima’s Executive Chairman, said: “This is an exciting step for Micrima as we transition from the product development phase into the market. We are pleased to be working with one of the best recognised global companies in breast imaging, and look forward to launching MARIA® into further new territories.”

Heinz Gerhards, Managing Director of Hologic Medicor DACH, said: “We are excited to be working alongside Micrima in the introduction of this new technology to the wider market.”

Prof Iain Lyburn, Consultant Radiologist, Cheltenham General Hospital, said: “We have been involved in the evaluation of the MARIA® system for some time now and whilst it is currently offered as an adjunct to other imaging modalities, particularly where dense tissue is involved, the technique promises the exciting future ability to distinguish between tissue types. Any imaging modality that can readily give this sort of functional information has the potential to influence many points in the diagnostic and treatment pathways – there could be less need for biopsies and possibly a reduction in over treatment.”

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.